Gracell Biotechnologies Future Growth

Future criteria checks 0/6

Gracell Biotechnologies's earnings are forecast to decline at 5.5% per annum while its annual revenue is expected to grow at 65.1% per year. EPS is expected to grow by 19.8% per annum. Return on equity is forecast to be -31.7% in 3 years.

Key information

-5.5%

Earnings growth rate

19.8%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	65.1%
Future return on equity	-31.7%
Analyst coverage	Good
Last updated	10 Feb 2024

Recent future growth updates

Recent updates

AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)

Feb 21

Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform

Sep 22

Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment

Nov 26

Gracell ends IPO quiet period with favorable views from analysts

Feb 02

Earnings and Revenue Growth Forecasts

NasdaqGS:GRCL - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	90	-813	-689	N/A	4
12/31/2025	N/A	-706	-654	N/A	7
12/31/2024	N/A	-603	-601	N/A	8
12/31/2023	N/A	-491	-607	N/A	8
9/30/2023	N/A	-497	N/A	N/A	N/A
6/30/2023	N/A	-601	-594	-560	N/A
3/31/2023	N/A	-601	N/A	N/A	N/A
12/31/2022	N/A	-608	-531	-483	N/A
9/30/2022	N/A	-605	N/A	N/A	N/A
6/30/2022	0	-563	-438	-381	N/A
3/31/2022	0	-513	N/A	N/A	N/A
12/31/2021	0	-454	-361	-305	N/A
9/30/2021	0	-425	N/A	N/A	N/A
6/30/2021	N/A	-365	N/A	N/A	N/A
3/31/2021	N/A	-332	N/A	N/A	N/A
12/31/2020	N/A	-275	-278	-198	N/A
9/30/2020	N/A	-228	-243	-167	N/A
12/31/2019	N/A	-201	-192	-135	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GRCL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GRCL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GRCL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GRCL is forecast to have no revenue next year.

High Growth Revenue: GRCL is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GRCL is forecast to be unprofitable in 3 years.

Gracell Biotechnologies Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 9.7% to US$10.58

Price target decreased by 11% to US$11.43

Price target decreased by 12% to US$12.57

Price target decreased to US$19.00

Price target decreased to US$28.33

Forecast to breakeven in 2025

Recent updates

Gracell Biotechnologies Files Form 15

AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. (NasdaqGS:GRCL) from a group of shareholders.

Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Composite Index

AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. (NasdaqGS:GRCL) from a group of shareholders.

AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)

Price target decreased by 9.7% to US$10.58

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

Gracell Biotechnologies Inc. Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma At ASH 2023

Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Price target decreased by 11% to US$11.43

Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65h American Society of Hematology Annual Meeting & Exposition

Gracell Biotechnologies Inc. to Present Data Highlighting Preclinical Efficacy of Smart Cart Against Solid Tumors At Society for Immunotherapy of Cancer 38th Annual Meeting

Gracell Biotechnologies Inc. to Report Q3, 2023 Results on Nov 13, 2023

Gracell Biotechnologies Reports Updated Clinical Data for Fastcar-T Gc012f for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate

Gracell Biotechnologies Doses First Patient in Phase 1B/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

Founder notifies of intention to sell stock

New minor risk - Shareholder dilution

Gracell Biotechnologies Inc. announced that it expects to receive $150.008003 million in funding from a group of investors

Gracell Biotechnologies Inc. announced that it expects to receive $150.008003 million in funding from a group of investors

Gracell Biotechnologies Inc. to Report Q2, 2023 Results on Aug 14, 2023

Founder notifies of intention to sell stock

Gracell Biotechnologies Inc. Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate

Gracell Biotechnologies Inc., Annual General Meeting, Jul 13, 2023

Gracell Biotechnologies Inc. Initiates Investigational Study Evaluating Gc012f for Treatment of Refractory Systemic Lupus Erythematosus

Founder notifies of intention to sell stock

Price target decreased by 12% to US$12.57

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

Gracell Biotechnologies Inc. Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma

Gracell Biotechnologies Inc. Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate

Founder notifies of intention to sell stock

Less than half of directors are independent

Founder notifies of intention to sell stock

Gracell Biotechnologies Inc. to Report Q3, 2022 Results on Nov 14, 2022

Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-Cell Acute Lymphoblastic Leukemia

Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform

Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.02

Gracell Biotechnologies Inc. to Report Q2, 2022 Results on Aug 15, 2022

Gracell Biotechnologies Inc. Appoints Dr. Wendy Li as Chief Medical Officer

Gracell Biotechnologies rallies after naming new chief medical officer

Gracell Biotechnologies Inc. Appoints Veteran Biopharma Executive Dr. Samuel Zhang as Chief Business Officer

Gracell names Dr. Samuel Zhang as Chief Business Officer

Chief Medical Officer notifies of intention to sell stock

Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-Targeting FasTCAR GC012F in RRMM at EHA2022 Congress

Gracell Biotechnologies Inc. to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting Car-T GC012f for Relapsed/Refractory Multiple Myeloma At 2022 ASCO Annual Meeting

Price target decreased to US$19.00

Gracell Biotechnologies Inc. to Report Q1, 2022 Results on May 16, 2022

Less than half of directors are independent

Gracell Biotechnologies Inc. Announces Early Results of First-In-Human Clinical Study of GC502 for Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Price target decreased to US$28.33

Gracell Biotechnologies Inc. to Report Q4, 2021 Results on Mar 14, 2022

Gracell Biotechnologies Inc. Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform

Gracell Biotechnologies Inc. Doses First Patients in First-In-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma

Chief Medical Officer notifies of intention to sell stock

Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment

Forecast to breakeven in 2025

Gracell Biotechnologies Inc. to Present Updated Results of Gc012f Fastcar-Enabled Bcma/Cd19 Dual-Targeting Car-T Cell Therapy for Relapsed/Refractory Multiple Myeloma At Asco 2021 and Eha 2021

Gracell Biotechnologies Inc. to Report Q4, 2020 Results on Mar 09, 2021

Gracell ends IPO quiet period with favorable views from analysts

Gracell Biotechnologies Inc. Receives IND Approval from China NMPA for GC019F

Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products

China NMPA Grants Approval to Gracell Biotechnologies Inc. for Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for Treatment of Relapsed or Refractory B-ALL

Gracell Biotechnologies Inc. has completed an IPO in the amount of $209 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts